2023 March 15

Three researchers from the Josep Carreras Institute receive grants from the AECC to promote research against leukemia

Last Monday, March 13, the Spanish Association Against Cancer (AECC) held an awards ceremony at their Barcelona headquarters for their 2022 research grants. Two researchers from the Josep Carreras Leukaemia Research Institute, Dr. Jeanine Diesch and Dr. Talia Velasco, received grants addressed to researchers. In addition, Dr. Marcus Buschbeck received funding for a general fundamental research project.

The AECC grants will enable researchers to further their lines of research, focused on gaining new knowledge about various types of leukemia and improving treatments.  These are the awarded projects from IJC:

Dr. Jeanine Diesch, a postdoctoral researcher in the Chromatin, Metabolism and Cell Fate laboratory, will search for new ways to overcome resistance to treatments thanks to the combination of existing therapies. Her results will open the door to designing clinical trials quickly and without having to wait for the development of new drugs.

Dr. Talia Velasco, from the Stem Cell Biology, Developmental Leukemia and Immunotherapy group, focuses her efforts on preventing relapse in patients with acute myeloid leukemia by developing new therapeutic strategies to increase their survival and disease-free time.

Dr. Marcus Buschbeck, head of the Chromatin, Metabolism and Cell Fate group, will develop a project aimed to better understand the epigenetic regulation of the bone marrow as a way to prevent the onset of hematological cancers.

At the event, which was attended by Dr. Laureano Molins, President of the AECC Barcelona and Ms. Isabel Orbe, Director General of the Scientific Foundation of the AECC, the association awarded 30 grants corresponding to the Barcelona area, out of the 195 grants awarded at the national level. During the event, debates and round tables were held between some of the researchers who received the grants.

The objectives of the call are to deepen the knowledge of cancer and the development of new therapeutic strategies, in order to achieve a 70% overall cancer survival rate by 2030.